NAD+ (injectable)
naturally occurring coenzyme (a dinucleotide, not a peptide)
Also called: elamipretide, Forzinity, Bendavia, MTP-131, D-Arg-Dmt-Lys-Phe-NH2
SS-31 is a four-amino-acid peptide that concentrates in the inner membrane of mitochondria, where it binds cardiolipin, a lipid needed for efficient energy production. Under the name elamipretide (Forzinity), it became the first FDA-approved mitochondria-targeted drug in September 2025, for the rare genetic disease Barth syndrome.
It is discussed in longevity and endurance circles as a 'mitochondria repair' peptide, largely because of striking results in aged mice.
Human evidence: approved drug (for a different use). Approved (accelerated) only for Barth syndrome; a large trial in primary mitochondrial myopathy was negative; there are no trials in healthy or athletic people.
Not named on the 2026 list. Since its 2025 FDA approval it is no longer covered by the S0 non-approved catch-all, and its mechanism does not fit an S2 or S4 subsection.
Probably low, but unconfirmed; it is not explicitly cleared either. Check Global DRO or USADA. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
FDA-approved as Forzinity (elamipretide HCl) on Sept 19, 2025 under accelerated approval for Barth syndrome (patients at least 30 kg). Any other use is off-label, and 'research' SS-31 is not the approved product. It is not on the interim 503A categories list.
As of 2026-10-01.
Not named on the 2026 list. Since its 2025 FDA approval it is no longer covered by the S0 non-approved catch-all, and its mechanism does not fit an S2 or S4 subsection. Probably low, but unconfirmed; it is not explicitly cleared either. Check Global DRO or USADA. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
FDA-approved as Forzinity (elamipretide HCl) on Sept 19, 2025 under accelerated approval for Barth syndrome (patients at least 30 kg). Any other use is off-label, and 'research' SS-31 is not the approved product. It is not on the interim 503A categories list.
Approved drug (for a different use). Approved (accelerated) only for Barth syndrome; a large trial in primary mitochondrial myopathy was negative; there are no trials in healthy or athletic people.
Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.
naturally occurring coenzyme (a dinucleotide, not a peptide)
synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice
synthetic peptide based on thymosin beta-4, an actin-binding protein found in most cells